A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

ClinicalTrials.gov ID: NCT01987427

Public ClinicalTrials.gov record NCT01987427. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

APD356-A001-402 is a multicenter, double-blind, randomized, parallel-group pilot study of 12-week duration in overweight and obese adults. Approximately 225 subjects will be randomized to one of three treatment arms in a ratio 1:1:1 and will receive the combinations of lorcaserin 10 mg twice daily (BID) plus immediate-release phentermine-HCl 15 mg BID or 15 mg once daily (QD), or lorcaserin alone.

Study identification

NCT ID: NCT01987427
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Eisai Inc.; Industry
Enrollment: 344 participants

Conditions and interventions

Conditions

Chronic Weight Management

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 60 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 30, 2013 (Actual)
Primary completion: Aug 2014 (Actual)
Completion: Sep 3, 2014 (Actual)
Last update posted: Sep 30, 2019

2013 – 2014

United States locations

U.S. sites: 13
U.S. states: 12
U.S. cities: 13

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	—
Radiant Research - Arizona	Chandler	Arizona	85224	—
Scripps Clinical Research Center	La Jolla	California	92037	—
Translational Research Institute for Metabolism and Diabetes	Orlando	Florida	32804	—
Pennington Biomedical Research Center	Baton Rouge	Louisiana	70808	—
Boston Medical Center	Boston	Massachusetts	—	—
Weill Cornell College	New York	New York	10065	—
Duke University	Durham	North Carolina	27710	—
Radiant Research - Columbus	Columbus	Ohio	43212	—
Radiant Research - South Carolina	Anderson	South Carolina	29621	—
Radiant Research - Dallas	Dallas	Texas	75231	—
National Clinical Research - Norfolk	Norfolk	Virginia	23502	—
National Clinical Research - Richmond	Richmond	Virginia	23294	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01987427, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 30, 2019 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01987427 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →